Showing 1301-1310 of 10904 results for "".
- Upadacitinib Shows Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-earlier-skin-barrier-restoration-than-dupilumab-in-atopic-dermatitis/2488646/A biomarker analysis from the head-to-head Level Up study found that upadacitinib produced early molecular and histologic changes consistent with restoration of the skin barrier in adults with moderate-to-severe atopic dermatitis (AD), with broader changes than dupilumab in the study’s optional b
- FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographismhttps://practicaldermatology.com/news/fda-approves-remibrutinib-as-first-treatment-for-symptomatic-dermographism/2488642/The FDA has approved Rhapsido (remibrutinib; Novartis) for adults with symptomatic dermographism (SD) whose disease is inadequately controlled with H1 antihistamines, according to an October 7 announcement from Novartis. The approval makes remibrutinib the first FDA-approved treatment spec
- Earlier-Onset Atopic Dermatitis Linked With Cow’s Milk Sensitization: Studyhttps://practicaldermatology.com/news/earlier-onset-atopic-dermatitis-linked-with-cows-milk-sensitization-study/2488641/Egg and cow’s milk were the most common food allergens identified by skin prick testing among infants with atopic dermatitis (AD) in a 17-year retrospective study from Iran, although the investigators cautioned that testing alone cannot establish clinically confirmed food allergy. Publishe
- Sun Pharma Establishes $2.5 Million Dermatology Professorship at Mount Sinaihttps://practicaldermatology.com/news/sun-pharma-establishes-25-million-dermatology-professorship-at-mount-sinai/2488636/Sun Pharma has established an endowed dermatology professorship at the Icahn School of Medicine at Mount Sinai, naming longtime psoriasis researcher and academic dermatologist Mark G. Lebwohl, MD, as its inaugural holder. Supported by a $2.5 million endowment from Sun Pharma, the Sun Profe
- International Consortium of Mohs Surgery Launches to Support Global Collaboration in Skin Cancer Carehttps://practicaldermatology.com/news/international-consortium-of-mohs-surgery-launches-to-support-global-collaboration-in-skin-cancer-care/2488635/The International Consortium of Mohs Surgery (ICMS) has officially launched as a global professional association focused on advancing Mohs micrographic surgery and cutaneous oncology through education, research, collaboration, and professional exchange. ICMS leadership signed the organizat
- Emblation Names Four Medical Affairs Advisors for SwiftProhttps://practicaldermatology.com/news/emblation-names-four-medical-affairs-advisors-for-swiftpro/2488631/Emblation has appointed four clinicians and podiatry experts as Medical Affairs Advisors to support clinical education initiatives surrounding its SwiftPro microwave therapy system, which the company said recently received US Food and Drug Administration (FDA) 510(k) cleara
- Environmental Exposures, Skin Barrier Care Take Focus in Pediatric AD Consensushttps://practicaldermatology.com/news/environmental-exposures-skin-barrier-care-take-focus-in-pediatric-ad-consensus/2488624/Environmental exposures early in childhood that affect the skin barrier may contribute to the development of atopic dermatitis, and impact its severity, according to a new expert consensus published in the Journal of Drugs in Dermatology. The SAIGE III report examined current evid
- Short-Course Vunakizumab Shows Rapid Improvement in Pediatric GPPhttps://practicaldermatology.com/news/short-course-vunakizumab-shows-rapid-improvement-in-pediatric-generalized-pustular-psoriasis/2488622/Short-course treatment with vunakizumab was temporally associated with rapid improvement of acute generalized pustular psoriasis (GPP) flares in 3 pediatric patients, according to a case series published in Frontiers in Immunology. Vunakizumab Treatment in Pediatric GPP Flares
- Dr. Shawn Kwatra Analyzes ADtouch Data on Hand and Foot Atopic Dermatitishttps://practicaldermatology.com/news/dr-shawn-kwatra-analyzes-adtouch-data-on-hand-and-foot-atopic-dermatitis/2488634/New Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas, according to study investigator Shawn Kwatra, MD.
- Litifilimab Meets Primary Endpoint in Phase 2 Cutaneous Lupus Studyhttps://practicaldermatology.com/news/litifilimab-meets-primary-endpoint-in-phase-2-cutaneous-lupus-study/2488613/Biogen reported positive phase 2 results from Part A of the phase 2/3 AMETHYST study evaluating litifilimab in patients with cutaneous lupus erythematosus (CLE), with the investigational therapy meeting the study’s primary endpoint and showing improvement across several mea